MLYS
Mineralys Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.21
−0.21%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-63.5%
Return on equity
-52.3%
Return on assets
-57.2%
Return on invested capital
0.00x
Asset turnover
-$138.8M
Cash from operations
$7.48
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026